Search

everythinglearnresearchcommunity

for

Search:↓

% free PSA and urinary markers help better identify prostate cancer.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

The workshop highlighted the genetic links and psychological impacts of hair loss and skin disorders.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.

5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.

Male pattern baldness may predict prostate cancer risk.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

Finasteride may help prevent prostate cancer.

More biopsy cores and MRI before biopsy can improve prostate cancer detection.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.